Viridian Therapeutics (VRDN) shares are in focus after announcing a royalty financing agreement with DRI Healthcare. This deal could provide up to $300 million in non-dilutive funding to support the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback